Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Autor: | Ren H; External Affairs, Diabetes & CV, Novo Nordisk Denmark A/S, Copenhagen, Denmark., Berry S; Market Access, Novo Nordisk Ltd, Gatwick, UK., Malkin SJP; Ossian Health Economics and Communications GmbH, Basel, Switzerland malkin@ossianconsulting.com., Hunt B; Ossian Health Economics and Communications GmbH, Basel, Switzerland., Bain S; Swansea University Medical School, Swansea, UK. |
---|---|
Jazyk: | angličtina |
Zdroj: | BMJ open [BMJ Open] 2023 Sep 29; Vol. 13 (9), pp. e070473. Date of Electronic Publication: 2023 Sep 29. |
DOI: | 10.1136/bmjopen-2022-070473 |
Abstrakt: | Objectives: Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available. The present study evaluated the long-term cost-effectiveness of initiating oral semaglutide versus continuing metformin plus sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy in the UK. Design: Outcomes were projected over patients' lifetimes using the IQVIA Core Diabetes Model (V.9.0). Clinical data were taken from the oral semaglutide and placebo arms of the patient subgroup receiving metformin plus an SGLT-2 inhibitor in PIONEER 4. Costs, expressed in 2021 Pounds sterling (GBP), were accounted from a healthcare payer perspective. Interventions: Modelled patients received oral semaglutide immediately (in the first year of the analysis) or after a 2-year delay, after which all physiological parameters were brought to values observed in the immediate therapy arm. During the simulation, patients intensified with the addition of basal insulin and, subsequently, by switching to basal-bolus insulin. Results: Immediate oral semaglutide therapy was associated with improvements in life expectancy of 0.17 (95% CIs 0.16 to 0.19) years, and quality-adjusted life expectancy of 0.15 (0.14 to 0.16) quality-adjusted life years (QALYs), versus a 2-year delay. Benefits were due to a reduced incidence of diabetes-related complications. Direct costs were estimated to be GBP 1423 (1349 to 1496) higher with immediate oral semaglutide therapy versus a 2-year delay, with higher treatment costs partially offset by cost savings from avoidance of diabetes-related complications. Immediate oral semaglutide therapy was therefore associated with an incremental cost-effectiveness ratio of GBP 9404 (8380 to 10 538) per QALY gained versus a 2-year delay. Conclusions: Immediate oral semaglutide is likely to represent a cost-effective treatment in people with type 2 diabetes with inadequate glycaemic control on metformin plus an SGLT-2 inhibitor in the UK. Trial Registration Number: NCT02863419. Competing Interests: Competing interests: HR is an employee of Novo Nordisk Denmark A/S. SBe is an employee of Novo Nordisk Ltd. SJPM and BH are employees of Ossian Health Economics and Communications, which received consulting fees from Novo Nordisk Denmark A/S to support preparation of the analysis. SBa has received honoraria, teaching and research sponsorship/grants from the following: AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi and Takeda. SBa owns a share of Glycosmedia. (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
Databáze: | MEDLINE |
Externí odkaz: |